Aviva
NAGE

Aviva’s Niagen Bioscience NAGE Stock Holding History

Aviva’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$393K Buy
123,323
+31,202
+34% +$127K ﹤0.01% 809
2026
Q1 		$406K Buy
92,121
+17,894
+24% +$96.6K ﹤0.01% 790
2025
Q4 		$472K Buy
74,227
+24,426
+49% +$170K ﹤0.01% 807
2025
Q3 		$465K Buy
49,801
+10,710
+27% +$108K ﹤0.01% 805
2025
Q2 		$563K Sell
39,091
-13,964
-26% -$138K ﹤0.01% 685
2025
Q1 		$366K Buy
+53,055
New +$333K ﹤0.01% 831

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Aviva's NAGE Position: Q2 2026 in Review

Aviva increased its Niagen Bioscience (NAGE) stake by 34% in Q2 2026, buying an estimated $127K and bringing the position to 123,323 shares worth $393K. The position accounts for ﹤0.01% of the portfolio, ranked #809.

Aviva first reported a position in NAGE in Q1 2025 and has held it in 6 quarters since. The position peaked at $563K in Q2 2025. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Aviva held 123,323 shares of Niagen Bioscience worth $393K as of Q2 2026.
  • Aviva bought 31,202 Niagen Bioscience shares in Q2 2026, an estimated $127K.
  • Niagen Bioscience made up ﹤0.01% of Aviva's portfolio in Q2 2026, its #809 holding.
  • Aviva first reported a position in Niagen Bioscience in Q1 2025 and has held it in 6 quarters since.
  • Aviva's Niagen Bioscience position peaked at $563K in Q2 2025.
  • 140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.